3-[(E)-2-pyridin-3-ylethenyl]-1H-quinoxalin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-[(E)-2-pyridin-3-ylethenyl]-1H-quinoxalin-2-one
• 化学式: C₁₅H₁₁N₃O
• 分子量: 249.27
• InChiKey: WOYMZRWUKAMJMT-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
  申请人：——

  公开号：US20040266668A1

  公开（公告）日：2004-12-30

  The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: 1 which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I或II的化合物，或其药学上可接受的盐、酯或前药：1，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及含有上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者投予含有本发明化合物的药物组合物来治疗HCV感染的方法。
• QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Nakajima Suanne

  公开号：US20100015092A1

  公开（公告）日：2010-01-21

  The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及公式I或II的化合物，或其药学上可接受的盐、酯或前药，其抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶NS3-NS4A的活性。因此，本发明的化合物干扰了丙型肝炎病毒的生命周期，也可用作抗病毒药物。本发明还涉及包含上述化合物的制药组合物，用于治疗患有丙型肝炎感染的受试者。本发明还涉及通过给予包含本发明化合物的制药组合物来治疗受试者的丙型肝炎感染的方法。
• EP1615613A2
  申请人：——

  公开号：EP1615613A2

  公开（公告）日：2006-01-18
• EP1615613A4
  申请人：——

  公开号：EP1615613A4

  公开（公告）日：2007-02-14
• US7176208B2
  申请人：——

  公开号：US7176208B2

  公开（公告）日：2007-02-13